Evidence map›Paper›PMID 40356983›Full record

ArticleFrontiers in pharmacology2025

Genetic polymorphisms in

Ahmed Essam Abou Warda, Rylie M Flohr, Rania M Sarhan, Mohamed Nabil Salem, Heba F Salem, Ayman N Moharram, Abdullah S Alanazi, Christelle Lteif, Brian E Gawronski, Leanne Dumeny and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ahmed Essam Abou WardaDepartment of Clinical Pharmacy, Faculty of Pharmacy, October 6 University, Giza, Egypt.
Rylie M FlohrCenter for Pharmacogenomics and Precision Medicine and Department for Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, United States.
Rania M SarhanDepartment of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Mohamed Nabil SalemDepartment of Internal Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Heba F SalemDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Ayman N MoharramDepartment of Critical Care Medicine, Faculty of Medicine, Cairo University, Giza, Egypt.
Abdullah S AlanaziDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Christelle LteifCenter for Pharmacogenomics and Precision Medicine and Department for Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, United States.
Brian E GawronskiCenter for Pharmacogenomics and Precision Medicine and Department for Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, United States.
Leanne DumenyCenter for Pharmacogenomics and Precision Medicine and Department for Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, United States.
Tariq G AlsahliDepartment of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Khaled EleniziDepartment of Internal Medicine, College of Medicine, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia.
Bassem ZarifDepartment of Cardiology, National Heart Institute, Giza, Egypt.
Neven SarhanDepartment of Clinical Pharmacy, Faculty of Pharmacy, Misr International University, Cairo, Egypt.
Julio D DuarteCenter for Pharmacogenomics and Precision Medicine and Department for Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, United States.

Funding

Training Program for Applied Research and Development in Genomic MedicineT32HG008958 · NHGRI · UNIVERSITY OF FLORIDA · 2022 to 2025
$1.0M
NHGRI NIH HHS T32 HG008958
6 · The paper itself

Abstract

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as promising therapeutics for heart failure (HF). Nevertheless, evidence supporting the mechanism of SGLT2i efficacy in HF patients is currently limited. Genetic variation in Methods: We analyzed two HF cohorts to identify variants associated with SGLT2i response pathways. Adjusted Cox proportional-hazard regression models were used to assess the effect of Results: In SGLT2i-naïve patients, rs3813008 (SLC5A2) was significantly associated with reduced risk of the composite outcome of all-cause death or hospitalization (HR = 0.65, 95% CI: 0.47-0.89, P = 0.008). In the dapagliflozin-treated cohort, rs3813008 was also associated with death or hospitalization, but with increased risk in treated patients (HR = 3.38, 95% CI: 1.35-8.42, P = 0.008). Conclusion: Our study suggests that

Indexed as

dapagliflozingene-drug interactionsheart failuresingle nuceotide polymorphismsodium-glucose transporter 2 inhibitors

Identifiers

PMID40356983
PMCPMC12066643

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.